SESSION I

Acute leukemia

BiTes in AML
M. Subklewe
IDH inhibitors
E.M. Stein
HDM2 inhibitor
E.M. Stein
FLT3 inhibitors
A.E. Perl
SESSION II

Hodgkin’s lymphoma

AFM13
S.M. Ansell
CAR-T
C.A. Ramos
Lectures

Siltuximab
F. van Rhee
Moxetumomab pasudotox
R.J. Kreitman
SESSION III

Chronic myeloid leukemia

Ponatinib
G. Rosti
Bosutinib
V. Garcia-Gutierrez
SESSION IV

Classical Ph1-neg myeloproliferative neoplasms

SESSION V

Non-Hodgkin’s lymphoma (I)

Glofitamab
Dickinson
Mosunetuzumab
E.L. Budde
Odronextamab
M.S. Topp
SESSION VI

Non-Hodgkin’s lymphoma (II)

Zilovertamab
M. Wang
Pirtobrutinib
M. Wang
Selinexor
J. Kuruvilla
Valemetostat
F. Foss
SESSION VII

Non-Hodgkin’s lymphoma - PI3K inhibitors (III)

Umbralisib
E. Marchi
Copanlisib
M.J. Matasar
Zandelisib
A.D. Zelenetz
Lecture

SESSION VIII

Chronic Lymphocitic Leukemia

Idelalisib
A.D. Zelenetz
Pirtobrutinib
A.R. Mato
Duvelisib
A.R. Mato
SESSION IX

Multiple myeloma